<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
  <head>
    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
    		<meta name="keywords" content="Anakinra,Anakinra.png,Immunosuppressants,Immunosuppressants,ATC code L04,Abatacept,Adalimumab,Afelimomab,Alefacept,Allergy,Amgen" />
		<link rel="shortcut icon" href="/favicon.ico" />
		<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (English)" />
		<link rel="copyright" href="../../../COPYING.html" />
    <title>Anakinra - Wikipedia, the free encyclopedia</title>
    <style type="text/css">/*<![CDATA[*/ @import "../../../skins/htmldump/main.css"; /*]]>*/</style>
    <link rel="stylesheet" type="text/css" media="print" href="../../../skins/common/commonPrint.css" />
    <!--[if lt IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE50Fixes.css";</style><![endif]-->
    <!--[if IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE55Fixes.css";</style><![endif]-->
    <!--[if IE 6]><style type="text/css">@import "../../../skins/monobook/IE60Fixes.css";</style><![endif]-->
    <!--[if IE]><script type="text/javascript" src="../../../skins/common/IEFixes.js"></script>
    <meta http-equiv="imagetoolbar" content="no" /><![endif]-->
    <script type="text/javascript" src="../../../skins/common/wikibits.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/md5.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/utf8.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/lookup.js"></script>
    <script type="text/javascript" src="../../../raw/gen.js"></script>        <style type="text/css">/*<![CDATA[*/
@import "../../../raw/MediaWiki%7ECommon.css";
@import "../../../raw/MediaWiki%7EMonobook.css";
@import "../../../raw/gen.css";
/*]]>*/</style>          </head>
  <body
    class="ns-0">
    <div id="globalWrapper">
      <div id="column-content">
	<div id="content">
	  <a name="top" id="contentTop"></a>
	        <h1 class="firstHeading">Anakinra</h1>
	  <div id="bodyContent">
	    <h3 id="siteSub">From Wikipedia, the free encyclopedia</h3>
	    <div id="contentSub"></div>
	    	    <div class="usermessage">You have <a href="../../../1/2/7/User_talk%7E127.0.0.1.html" title="User talk:127.0.0.1">new messages</a> (<a href="../../../1/2/7/User_talk%7E127.0.0.1.html" title="User talk:127.0.0.1">last change</a>).</div>	    <!-- start content -->
	    <table id="drugInfoBox" style="float: right; clear: right; margin: 0 0 0.5em 1em; background: #ffffff;" class="toccolours" border="0" cellpadding="1" align="right" width="280">
<tr>
<td align="center" colspan="2"><a href="../../../a/n/a/Image%7EAnakinra.png_b526.html" class="image" title=""><img src="../../../upload/shared/thumb/7/7c/Anakinra.png/220px-Anakinra.png" alt="" width="220" height="253" longdesc="../../../a/n/a/Image%7EAnakinra.png_b526.html" /></a></td>
</tr>
<tr>
<td align="center" colspan="2">
<div style="font-size:medium; line-height:167%;">Anakinra</div>
</td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Systematic (<a href="../../../i/n/t/International_Union_of_Pure_and_Applied_Chemistry_nomenclature_efd4.html" title="International Union of Pure and Applied Chemistry nomenclature">IUPAC</a>) name</b></td>
</tr>
<tr>
<td bgcolor="#EEEEEE" style="text-align: center; vertical-align: top;" colspan="2"><span style="font-size:11px">Recombinant human Interleukin-1 receptor antagonist protein; syn. N2-l-methionyl-interleukin 1 receptor antagonist (human isoform x reduced)</span></td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Identifiers</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" width="90"><a href="../../../c/a/s/CAS_registry_number_4b20.html" title="CAS registry number">CAS number</a></td>
<td bgcolor="#EEEEEE"><span class="reflink plainlinksneverexpand"><a href="http://www.nlm.nih.gov/cgi/mesh/2006/MB_cgi?term=143090-92-0&amp;rn=1" class="external text" title="http://www.nlm.nih.gov/cgi/mesh/2006/MB_cgi?term=143090-92-0&amp;rn=1" rel="nofollow">143090-92-0</a></span></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="../../../a/n/a/Anatomical_Therapeutic_Chemical_Classification_System_186e.html" title="Anatomical Therapeutic Chemical Classification System">ATC code</a></td>
<td bgcolor="#EEEEEE"><a href="../../../a/t/c/ATC_code_L04_d7fc.html" title="ATC code L04">L04</a><span class="reflink plainlinksneverexpand"><a href="http://www.whocc.no/atcddd/indexdatabase/index.php?query=L04AA14" class="external text" title="http://www.whocc.no/atcddd/indexdatabase/index.php?query=L04AA14" rel="nofollow">AA14</a></span></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="../../../p/u/b/PubChem_a50b.html" title="PubChem">PubChem</a></td>
<td bgcolor="#EEEEEE">&#160;?</td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="../../../d/r/u/DrugBank_2050.html" title="DrugBank">DrugBank</a></td>
<td bgcolor="#EEEEEE"><span class="reflink plainlinksneverexpand"><a href="http://redpoll.pharmacy.ualberta.ca/drugbank/cgi-bin/getCard.cgi?CARD=BTD00060" class="external text" title="http://redpoll.pharmacy.ualberta.ca/drugbank/cgi-bin/getCard.cgi?CARD=BTD00060" rel="nofollow">BTD00060</a></span></td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Chemical data</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="../../../c/h/e/Chemical_formula.html" title="Chemical formula">Formula</a></td>
<td bgcolor="#EEEEEE"><a href="../../../c/a/r/Carbon.html" title="Carbon"><span style="color: rgb(000,000,000); font-weight: bold;">C</span></a><sub>759</sub><a href="../../../h/y/d/Hydrogen.html" title="Hydrogen"><span style="color: rgb(154,154,154); font-weight: bold;">H</span></a><sub>1186</sub><a href="../../../n/i/t/Nitrogen.html" title="Nitrogen"><span style="color: rgb(000,000,255); font-weight: bold;">N</span></a><sub>208</sub><a href="../../../o/x/y/Oxygen.html" title="Oxygen"><span style="color: rgb(232,070,070); font-weight: bold;">O</span></a><sub>232</sub><a href="../../../s/u/l/Sulfur.html" title="Sulfur"><span style="color: rgb(229,197,063); font-weight: bold;">S</span></a><sub>10</sub><sup>&#160;</sup></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="../../../m/o/l/Molecular_mass.html" title="Molecular mass">Mol. mass</a></td>
<td bgcolor="#EEEEEE">17,257.6 g/mol</td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Pharmacokinetic data</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../b/i/o/Bioavailability.html" title="Bioavailability">Bioavailability</a></td>
<td bgcolor="#EEEEEE">95%</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../d/r/u/Drug_metabolism.html" title="Drug metabolism">Metabolism</a></td>
<td bgcolor="#EEEEEE">predominantly renal</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../b/i/o/Biological_half-life.html" title="Biological half-life">Half life</a></td>
<td bgcolor="#EEEEEE">4-6 hrs</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../e/x/c/Excretion.html" title="Excretion">Excretion</a></td>
<td bgcolor="#EEEEEE">&#160;?</td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Therapeutic considerations</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../p/r/e/Pregnancy_category.html" title="Pregnancy category">Pregnancy cat.</a></td>
<td bgcolor="#EEEEEE">
<p>B (in some countries&#160;: contraindicated)</p>
</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../r/e/g/Regulation_of_therapeutic_goods.html" title="Regulation of therapeutic goods">Legal status</a></td>
<td bgcolor="#EEEEEE">
<p>Rx only, not a controlled substance</p>
</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../r/o/u/Route_of_administration.html" title="Route of administration">Routes</a></td>
<td bgcolor="#EEEEEE">s.c. injection only</td>
</tr>
</table>
<p><b>Anakinra</b> is a <a href="../../../d/r/u/Drug.html" title="Drug">drug</a>, mostly used to treat <a href="../../../r/h/e/Rheumatoid_arthritis.html" title="Rheumatoid arthritis">rheumatoid arthritis</a>.</p>
<table id="toc" class="toc" summary="Contents">
<tr>
<td>
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1"><a href="#Basic_Chemical.2C_Pharmacological_and_Marketing_Data"><span class="tocnumber">1</span> <span class="toctext">Basic Chemical, Pharmacological and Marketing Data</span></a></li>
<li class="toclevel-1"><a href="#Indications"><span class="tocnumber">2</span> <span class="toctext">Indications</span></a></li>
<li class="toclevel-1"><a href="#Contraindications_and_Precautions"><span class="tocnumber">3</span> <span class="toctext">Contraindications and Precautions</span></a></li>
<li class="toclevel-1"><a href="#Side-Effects"><span class="tocnumber">4</span> <span class="toctext">Side-Effects</span></a></li>
<li class="toclevel-1"><a href="#Recommended_Laboratory_Tests"><span class="tocnumber">5</span> <span class="toctext">Recommended Laboratory Tests</span></a></li>
<li class="toclevel-1"><a href="#Malignancies"><span class="tocnumber">6</span> <span class="toctext">Malignancies</span></a></li>
<li class="toclevel-1"><a href="#Interactions"><span class="tocnumber">7</span> <span class="toctext">Interactions</span></a></li>
<li class="toclevel-1"><a href="#Dosage_Regime"><span class="tocnumber">8</span> <span class="toctext">Dosage Regime</span></a></li>
<li class="toclevel-1"><a href="#Duration_of_treatment"><span class="tocnumber">9</span> <span class="toctext">Duration of treatment</span></a></li>
<li class="toclevel-1"><a href="#Possible_future_Indications"><span class="tocnumber">10</span> <span class="toctext">Possible future Indications</span></a></li>
<li class="toclevel-1"><a href="#References_and_External_Links"><span class="tocnumber">11</span> <span class="toctext">References and External Links</span></a></li>
</ul>
</td>
</tr>
</table>
<p><script type="text/javascript">
//<![CDATA[
 if (window.showTocToggle) { var tocShowText = "show"; var tocHideText = "hide"; showTocToggle(); } 
//]]>
</script><a name="Basic_Chemical.2C_Pharmacological_and_Marketing_Data" id="Basic_Chemical.2C_Pharmacological_and_Marketing_Data"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/a/Anakinra.html" title="Edit section: Basic Chemical, Pharmacological and Marketing Data">edit</a>]</span> <span class="mw-headline">Basic Chemical, Pharmacological and Marketing Data</span></h2>
<p>Anakinra is an <a href="../../../i/l/-/IL-1_a715.html" title="IL-1">interleukin-1</a> (IL-1) <a href="../../../r/e/c/Receptor_antagonist.html" title="Receptor antagonist">receptor antagonist</a>. The anakinra molecule is a recombinant, non glycosolated version of human IL-1RA (RA for receptor antagonist). It consists of 153 amino acids and has a molecular weight of 17,257.6 g/mol (approx. 17.3 kilodaltons) and differs from native human IL-1RA in that it has the addition of a single methionine residue on its amino terminus.</p>
<p>The substance is a biologic response modifier. It is prepared from cultures of genetically modified <i><a href="../../../e/s/c/Escherichia_coli.html" title="Escherichia coli">Escherichia coli</a></i> using recombinant DNA technology.</p>
<p>Anakinra blocks the biologic activity of naturally occurring IL-1, including <a href="../../../i/n/f/Inflammation.html" title="Inflammation">inflammation</a> and cartilage degradation associated with <a href="../../../r/h/e/Rheumatoid_arthritis.html" title="Rheumatoid arthritis">rheumatoid arthritis</a>, by competitively inhibiting the binding of IL-1 to the Interleukin-1 type <a href="../../../r/e/c/Receptor.html" title="Receptor">receptor</a>, which is expressed in many tissues and organs. IL-1 is produced in response to inflammatory stimuli and mediates various <a href="../../../p/h/y/Physiologic.html" title="Physiologic">physiologic</a> responses, including <a href="../../../i/n/f/Inflammatory.html" title="Inflammatory">inflammatory</a> and immunologic reactions. IL-1 additionally stimulates <a href="../../../b/o/n/Bone_resorption.html" title="Bone resorption">bone resorption</a> and induces tissue damage like cartilage degradation as a result of loss of <a href="../../../p/r/o/Proteoglycans.html" title="Proteoglycans">proteoglycans</a>. In patients with rheumatoid arthritis the natural IL-1 receptor antagonist is not found in effective concentrations in <a href="../../../s/y/n/Synovium.html" title="Synovium">synovium</a> and <a href="../../../s/y/n/Synovial_fluid.html" title="Synovial fluid">synovial fluid</a> to counteract the elevated IL-1 concentrations in these patients.</p>
<p>Anakinra had an absolute bioavailability of 95% for healthy adults (n = 11) after a 70 mg subcutaneous bolus injection. Peak plasma concentrations of Kineret® generally occurred 3 to 7 hours after s.c. administration of clinically relevant doses (1 to 2 mg/kg: n = 18) for patients with rheumatoid arthritis. The terminal half-life ranged from 4 to 6 hours. After daily s.c. dosing for up to 24 weeks, no unexpected accumulations of Kineret® were observed in the plasma samples of rheumatoid arthritis patients.</p>
<p>This drug is sold under the <a href="../../../t/r/a/Tradename.html" title="Tradename">tradename</a> "Kineret®" and is produced by the pharmaceutical company <a href="../../../a/m/g/Amgen.html" title="Amgen">Amgen</a>. It is delivered as injection concentrate containing 100mg each single dose.</p>
<p><a name="Indications" id="Indications"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/a/Anakinra.html" title="Edit section: Indications">edit</a>]</span> <span class="mw-headline">Indications</span></h2>
<p>Anakinra is indicated as monotherapeutic agent or in combination with other disease-modifying agents (DMARDs) other than <a href="../../../t/u/m/Tumor_necrosis_factor.html" title="Tumor necrosis factor">tumor necrosis factor α</a> (TNF-α) blocking agents (e.g., <a href="../../../a/d/a/Adalimumab.html" title="Adalimumab">adalimumab</a>, <a href="../../../e/t/a/Etanercept.html" title="Etanercept">etanercept</a>, <a href="../../../i/n/f/Infliximab.html" title="Infliximab">infliximab</a>) for the management of signs and symptoms of rheumatoid arthritis and to inhibit the progression of structural damage associated with the disease in adults with moderately to severely active disease who have had an absence of clinical improvement of symptoms or inadequate response in therapy with one or more DMARDs.</p>
<p>Kineret® showed moderate but statistically significant therapeutic efficacy; in most studies <a href="../../../m/e/t/Methotrexate.html" title="Methotrexate">methotrexate</a> was administered concomitantly. In the methotrexate plus anakinra group 38% of 250 patients reached an improvement/relief of symptoms of at least 20% within 24 weeks. In the control group of 251 patients under methotrexate treatment alone response was seen in 22% only. The clinical response was measured according to ACR-criteria (20, 50, and 70).</p>
<p>There are no direct studies comparing anakinra with TNF-α inhibitors, but indirect data suggests that anakinra may be inferior to TNF-α inhibitors. In a study with infliximab plus methotrexate 50% of all patients had significant remission (according to at least ACR 20 criteria) after a 30-week treatment period.</p>
<p><a name="Contraindications_and_Precautions" id="Contraindications_and_Precautions"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/a/Anakinra.html" title="Edit section: Contraindications and Precautions">edit</a>]</span> <span class="mw-headline">Contraindications and Precautions</span></h2>
<ul>
<li><a href="../../../h/y/p/Hypersensitivity.html" title="Hypersensitivity">Hypersensitivity</a> to anakinra, other E. coli derived proteins, or to any other ingredient (absolute contraindication).</li>
<li>Preexisting malignant diseases (e.g., solid <a href="../../../c/a/n/Cancer.html" title="Cancer">cancers</a>, <a href="../../../l/e/u/Leukemia.html" title="Leukemia">leukemia</a>): absolutely contraindicated (anakinra may be a human carcinogen and the suppression of immune function may worsen already existing malignancies).</li>
<li>Patients with <a href="../../../n/e/u/Neutropenia.html" title="Neutropenia">neutropenia</a> due to any reason&#160;: absolutely contraindicated. Neutrophil counts should be obtained before initiating therapy and regularly thereafter (see recommended laboratory tests).</li>
<li>Severely impaired <a href="../../../r/e/n/Renal_function.html" title="Renal function">renal function</a> (creatinine clearance less than 30 ml/minute): absolutely contraindicated.</li>
<li>Preexisting active <a href="../../../t/u/b/Tuberculosis.html" title="Tuberculosis">tuberculosis</a> (disease may be worsened – see side-effects).</li>
<li>Concomitant application of live-virus vaccines (see Interactions).</li>
<li><a href="../../../l/a/c/Lactation.html" title="Lactation">Lactation</a>: it is unknown if anakinra is distributed into human milk. Nursing mothers should either discontinue the drug or breast-feeding, taking into account the importance of the drug to the mother.</li>
<li>Pediatric patients: no well controlled human data exists in patients under age 18. Therefore, therapy is contraindicated in those patients.</li>
</ul>
<p>Precautions:</p>
<ul>
<li>Geriatric patients (over 65 yrs of age): risk of infections is increased.</li>
<li><a href="../../../a/s/t/Asthma.html" title="Asthma">Asthma</a>: increased risk of severe infections.</li>
<li>Women of childbearing potential should use effective <a href="../../../c/o/n/Contraception.html" title="Contraception">contraception</a> methods.</li>
<li>Pregnancy: animal studies showed no adverse effects. Human data is not available. The drug should be applied to pregnant women only if clearly indicated.</li>
<li>Mild to moderately impaired renal function: caution.</li>
</ul>
<p><a name="Side-Effects" id="Side-Effects"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/a/Anakinra.html" title="Edit section: Side-Effects">edit</a>]</span> <span class="mw-headline">Side-Effects</span></h2>
<ul>
<li><a href="../../../g/i/t/GIT_ed82.html" title="GIT">GIT</a>&#160;: Frequently, nausea (8%), diarrhea (7%), unspecific abdominal pain (5%).</li>
<li><a href="../../../a/l/l/Allergy.html" title="Allergy">Allergy</a>&#160;: Rare cases of allergic reactions including severe <a href="../../../a/n/a/Anaphylaxis.html" title="Anaphylaxis">anaphylaxis</a> have been noticed. If necessary, the usual symptomatic therapy with <a href="../../../c/o/r/Corticosteroids.html" title="Corticosteroids">corticosteroids</a>, <a href="../../../e/p/i/Epinephrine.html" title="Epinephrine">epinephrine</a>, antihistaminics and i.v. fluid correction should be initiated as soon as possible. Rare cases of allergic skin <a href="../../../r/a/s/Rash.html" title="Rash">rash</a> have also been seen.</li>
<li><a href="../../../r/e/s/Respiratory_tract.html" title="Respiratory tract">Respiratory tract</a>&#160;: Frequently, infections of upper respiratory tract (13%), <a href="../../../s/i/n/Sinusitis.html" title="Sinusitis">sinusitis</a> (7%), flu-like syndrome (6%), Infrequently, <a href="../../../p/n/e/Pneumonia.html" title="Pneumonia">pneumonia</a> and <a href="../../../t/u/b/Tuberculosis.html" title="Tuberculosis">tuberculosis</a>.</li>
<li><a href="../../../s/k/i/Skin.html" title="Skin">Skin</a>&#160;: Frequently <a href="../../../e/c/c/Ecchymoses.html" title="Ecchymoses">ecchymoses</a>, infrequently skin <a href="../../../m/y/c/Mycosis.html" title="Mycosis">mycosis</a>, Lupus-erythematodes-like syndrome, <a href="../../../u/r/t/Urticaria.html" title="Urticaria">urticaria</a>, and isolated cases of melanoma (see malignancies).</li>
<li><a href="../../../i/m/m/Immune_system.html" title="Immune system">Immune system</a>&#160;: Frequently, infections (40%, severe in 2%). Infrequently, production of <a href="../../../a/n/t/Antibodies.html" title="Antibodies">antibodies</a> with neutralizing activity.</li>
<li>Blood and blood forming organs&#160;: Frequently, decrease in neutrophil counts (8% under anakinra, placebo 2%), infrequent significant neutropenia (0.4% under anakinra), moderate <a href="../../../e/o/s/Eosinophilia.html" title="Eosinophilia">eosinophilia</a>, moderate <a href="../../../t/h/r/Thrombocytopenia.html" title="Thrombocytopenia">thrombocytopenia</a>, and malignant <a href="../../../l/y/m/Lymphoma.html" title="Lymphoma">lymphomas</a> (0.12 cases/patient year) (see malignancies).</li>
<li>Musculosceletal system&#160;: Infrequent are arthritic symptoms, arthritic symptoms associated with inflammation, bony infections.</li>
<li>Pain, inflammation, and erythema at injection sites&#160;: Very frequently (70% of patients), usually during first 4 weeks of therapy, reversible within 1 to 2 weeks. These reactions are reasons why many patients discontinue therapy.</li>
</ul>
<p><a name="Recommended_Laboratory_Tests" id="Recommended_Laboratory_Tests"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/a/Anakinra.html" title="Edit section: Recommended Laboratory Tests">edit</a>]</span> <span class="mw-headline">Recommended Laboratory Tests</span></h2>
<p>In patients receiving Kineret® a decrease in neutrophil counts may be found. In the placebo-controlled studies 8% of patients receiving anakinra had decreases in neutrophil counts of at least 1 World Health Organization (WHO) toxicity grade compared with 2% in the placebo control group. Kineret®-treated patients experienced defined neutropenia (ANC &lt; 1 x 109/L) in 0.4%.</p>
<p><b>Neutrophil counts should be assessed prior to initiating Kineret® treatment, and while receiving Kineret®, monthly for 3 months, and thereafter quarterly for a period up to 1 year.</b></p>
<p><a name="Malignancies" id="Malignancies"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/a/Anakinra.html" title="Edit section: Malignancies">edit</a>]</span> <span class="mw-headline">Malignancies</span></h2>
<p>Among 5,300 rheumatoid arthritis patients treated with Kineret® in clinical trials for a mean of 15 months (approximately 6,400 patient years of treatment), 8 cases of lymphomas were observed resulting in a rate of 0.12 cases/100 patient years. This is 3.6 fold higher than the rate of lymphomas expected in the general population. However, it should be noted that the 'natural' incidence of lymphomas in patients with rheumatoid arthritis is considerably increased and may even be higher in patients with high disease activity.</p>
<p>Additionally, 37 solid tumors of different origination have been found. Of these, the number of 3 melanomas reported in study 4 is significant (1 case expected), but the clear association to anakinra therapy remains unclear.</p>
<p><b>At this stage it cannot be ruled out that anakinra is a human carcinogen.</b></p>
<p><a name="Interactions" id="Interactions"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/a/Anakinra.html" title="Edit section: Interactions">edit</a>]</span> <span class="mw-headline"><a href="../../../i/n/t/Interactions.html" title="Interactions">Interactions</a></span></h2>
<ul>
<li>TNF-Blocking Agents:</li>
</ul>
<p>An increased incidence of serious infections and an increased risk of neutropenia have been seen when anakinra and etanercept were used concomitantly in patients with rheumatoid arthritis. Similar interactions can be anticipated for the combination therapy of anakinra together with other agents blocking TNF (alpha) (e.g., adalimumab, infliximab). Therefore, combined drug therapy with anakinra and any TNF-blocking agent is not recommended and should be avoided. Moreover, in a 24-week clinical study a regime with anakinra and etanercept did not provide any additional benefit to the patients.</p>
<ul>
<li>Methotrexate:</li>
</ul>
<p>Methotrexate has been coadministered with anakinra in quite extended clinical studies. Neither specific drug interactions nor increased toxicity of anakinra and/or methotrexate have been noticed. In animal models (rats) studying the effects of both drugs when coadminstered, no effects on clearing of both drugs form plasma or on the respective toxicologic properties have been seen. Therefore, the concomitant use of both disease modifiers in patients with rheumatoid arthritis can be regarded as safe.</p>
<ul>
<li>Vaccines:</li>
</ul>
<p>Live-virus vaccines should not be given to patients during anakinra treatment. Information is not available, if anakinra would affect the rate of secondary transmission of vaccine virus (e.g., measles or poliomyelitis viruses) following administration of a live virus vaccine or regarding any other effect of vaccination on patients receiving the drug. Due to the fact that anakinra decreases the immune response to antigens in general, vaccine efficacy may be reduced in patients receiving anakinra.</p>
<p><a name="Dosage_Regime" id="Dosage_Regime"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/a/Anakinra.html" title="Edit section: Dosage Regime">edit</a>]</span> <span class="mw-headline">Dosage Regime</span></h2>
<p>The usual dosage is 100mg subcutaneosly (s.c.) once a day. Dose reduction to 100mg s.c. every other day should be considered in patients with severe renal impairment, if these are treated in exceptional cases (see contraindications and precautions). No additional benefits of doses exceeding 100mg daily have been seen.</p>
<p><a name="Duration_of_treatment" id="Duration_of_treatment"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/a/Anakinra.html" title="Edit section: Duration of treatment">edit</a>]</span> <span class="mw-headline">Duration of treatment</span></h2>
<p>In the pre-clinical and clinical studies the usual duration of therapy was 24 weeks. It is possible to extend therapy to 48 weeks in patients with satisfying remission after 24 weeks to maintain clinically evident improvements. Under continued therapy anakinra has been shown to slow progression of disease over a period of at least 12 month evidenced by X-ray studies or other clinical examinations. Some experience with 48 to 60 weeks (15 months) treatment duration has already been gained and no evidence has been seen regarding additional toxicity.</p>
<p><a name="Possible_future_Indications" id="Possible_future_Indications"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/a/Anakinra.html" title="Edit section: Possible future Indications">edit</a>]</span> <span class="mw-headline">Possible future Indications</span></h2>
<p>Due to the specific mechanism of action of anakinra, a possible efficiency may be anticipated in patients with inflammatory joint diseases such as <a href="../../../p/s/o/Psoriatic_arthritis.html" title="Psoriatic arthritis">psoriatic arthritis</a>, and <a href="../../../s/p/o/Spondylarthritis.html" title="Spondylarthritis">spondylarthritis</a>. Possibly, anakinra may even benefit patients with destructive <a href="../../../o/s/t/Osteoarthritis.html" title="Osteoarthritis">osteoarthritis</a> in inflammatory phases. Kineret® may also be effective in pediatric patients with <a href="../../../j/u/v/Juvenile_rheumatoid_arthritis.html" title="Juvenile rheumatoid arthritis">juvenile rheumatoid arthritis</a> (JRA). <b>Clinical studies have not been initiated so far regarding these diseases. Currently, the use of anakinra in these patients is therefore not recommended.</b></p>
<p><a name="References_and_External_Links" id="References_and_External_Links"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/a/Anakinra.html" title="Edit section: References and External Links">edit</a>]</span> <span class="mw-headline">References and External Links</span></h2>
<ul>
<li>AHFS Database Online</li>
<li>Arzneimittel Datenbank (in German)</li>
<li><a href="http://www.kineretrx.com/" class="external text" title="http://www.kineretrx.com/" rel="nofollow">Kineret homepage</a></li>
<li><a href="http://www.rheuma-online.de/medikamente/anakinra-kineret/anakinra-zb-kineret/tumorrisiko.html" class="external free" title="http://www.rheuma-online.de/medikamente/anakinra-kineret/anakinra-zb-kineret/tumorrisiko.html" rel="nofollow">http://www.rheuma-online.de/medikamente/anakinra-kineret/anakinra-zb-kineret/tumorrisiko.html</a> (on the risk of cancerogenity (in German))</li>
<li><a href="http://www.rheuma-online.de/medikamente/anakinra-kineret/anakinra-zb-kineret/ausblicke-moegliche-zukuenftige-anwendungen-von-anakinra-kineret.html" class="external free" title="http://www.rheuma-online.de/medikamente/anakinra-kineret/anakinra-zb-kineret/ausblicke-moegliche-zukuenftige-anwendungen-von-anakinra-kineret.html" rel="nofollow">http://www.rheuma-online.de/medikamente/anakinra-kineret/anakinra-zb-kineret/ausblicke-moegliche-zukuenftige-anwendungen-von-anakinra-kineret.html</a> (same site on future indications)</li>
<li><a href="http://www.rheuma-online.de/medikamente/anakinra-kineret/anakinra-zb-kineret/anakinra-kineret-in-der-kinderrheumatologie.html" class="external free" title="http://www.rheuma-online.de/medikamente/anakinra-kineret/anakinra-zb-kineret/anakinra-kineret-in-der-kinderrheumatologie.html" rel="nofollow">http://www.rheuma-online.de/medikamente/anakinra-kineret/anakinra-zb-kineret/anakinra-kineret-in-der-kinderrheumatologie.html</a> (same site on possible pediatric indications)</li>
</ul>
<div class="NavFrame" style="clear:both;">
<div class="NavHead" style="background:#ccccff;">
<div class="noprint plainlinksneverexpand" style="background-color:transparent; padding:0; font-weight:normal; font-size:xx-small; color:#000000; white-space:nowrap; position:absolute; width:auto; left:0.5em;"><a href="../../../i/m/m/Template%7EImmunosuppressants_9ba4.html" title="Template:Immunosuppressants"><span title="View this template">v</span></a>&#160;<span style="font-size:80%;">•</span>&#160;<span style="color: #002bb8;" title="Discussion about this template">d</span>&#160;<span style="font-size:80%;">•</span>&#160;<a href="http://en.wikipedia.org../../../i/m/m/Template%7EImmunosuppressants_9ba4.html" class="external text" title="http://en.wikipedia.org../../../i/m/m/Template%7EImmunosuppressants_9ba4.html" rel="nofollow"><span style="color: #002bb8;" title="You can edit this template. Please use the preview button before saving.">e</span></a></div>
<b><a href="../../../i/m/m/Immunosuppressive_drug.html" title="Immunosuppressive drug">Immunosuppressants</a> (<a href="../../../a/t/c/ATC_code_L04_d7fc.html" title="ATC code L04">L04</a>)</b></div>
<div class="NavContent" style="margin:0.5em; font-size:0.9em;">
<p><a href="../../../a/b/a/Abatacept.html" title="Abatacept">Abatacept</a>, Abetimus, <a href="../../../a/d/a/Adalimumab.html" title="Adalimumab">Adalimumab</a>, <a href="../../../a/f/e/Afelimomab.html" title="Afelimomab">Afelimomab</a>, <strong class="selflink">Anakinra</strong>, <a href="../../../a/l/e/Alefacept.html" title="Alefacept">Alefacept</a>, Antilymphocyte immunoglobulin (horse), Antithymocyte immunoglobulin (rabbit), <a href="../../../a/s/e/Aselizumab.html" title="Aselizumab">Aselizumab</a>, <a href="../../../a/t/l/Atlizumab.html" title="Atlizumab">Atlizumab</a>, <a href="../../../a/t/o/Atorolimumab.html" title="Atorolimumab">Atorolimumab</a>, <a href="../../../a/z/a/Azathioprine.html" title="Azathioprine">Azathioprine</a>, <a href="../../../b/a/s/Basiliximab.html" title="Basiliximab">Basiliximab</a>, <a href="../../../b/e/l/Belatacept.html" title="Belatacept">Belatacept</a>, <a href="../../../b/e/l/Belimumab.html" title="Belimumab">Belimumab</a>, <a href="../../../b/e/r/Bertilimumab.html" title="Bertilimumab">Bertilimumab</a>, <a href="../../../c/e/d/Cedelizumab.html" title="Cedelizumab">Cedelizumab</a>, <a href="../../../c/i/c/Ciclosporin.html" title="Ciclosporin">Ciclosporin</a>, <a href="../../../c/i/t/Citilimumab.html" title="Citilimumab">Citilimumab</a>, <a href="../../../c/l/e/Clenoliximab.html" title="Clenoliximab">Clenoliximab</a>, <a href="../../../d/a/c/Daclizumab.html" title="Daclizumab">Daclizumab</a>, Difirolimus, Dofosirolimus, <a href="../../../d/o/r/Dorlimomab_aritox.html" title="Dorlimomab aritox">Dorlimomab aritox</a>, <a href="../../../e/c/u/Eculizumab.html" title="Eculizumab">Eculizumab</a>, <a href="../../../e/f/a/Efalizumab.html" title="Efalizumab">Efalizumab</a>, <a href="../../../e/l/s/Elsilimomab.html" title="Elsilimomab">Elsilimomab</a>, <a href="../../../e/n/l/Enlimomab.html" title="Enlimomab">Enlimomab</a>, <a href="../../../e/n/l/Enlimomab_pegol.html" title="Enlimomab pegol">Enlimomab pegol</a>, <a href="../../../e/r/l/Erlizumab.html" title="Erlizumab">Erlizumab</a>, <a href="../../../e/t/a/Etanercept.html" title="Etanercept">Etanercept</a>, <a href="../../../e/v/e/Everolimus.html" title="Everolimus">Everolimus</a>, <a href="../../../f/a/r/Faralimomab.html" title="Faralimomab">Faralimomab</a>, <a href="../../../f/o/n/Fontolizumab.html" title="Fontolizumab">Fontolizumab</a>, <a href="../../../g/a/l/Galiximab.html" title="Galiximab">Galiximab</a>, <a href="../../../g/a/v/Gavilimomab.html" title="Gavilimomab">Gavilimomab</a>, Gifosirolimus, <a href="../../../g/o/l/Golimumab.html" title="Golimumab">Golimumab</a>, <a href="../../../g/o/m/Gomiliximab.html" title="Gomiliximab">Gomiliximab</a>, <a href="../../../g/u/s/Gusperimus.html" title="Gusperimus">Gusperimus</a>, <a href="../../../i/n/f/Infliximab.html" title="Infliximab">Infliximab</a>, <a href="../../../i/n/o/Inolimomab.html" title="Inolimomab">Inolimomab</a>, <a href="../../../i/p/i/Ipilimumab.html" title="Ipilimumab">Ipilimumab</a>, <a href="../../../k/e/l/Keliximab.html" title="Keliximab">Keliximab</a>, <a href="../../../l/e/f/Leflunomide.html" title="Leflunomide">Leflunomide</a>, <a href="../../../l/e/r/Lerdelimumab.html" title="Lerdelimumab">Lerdelimumab</a>, <a href="../../../l/u/m/Lumiliximab.html" title="Lumiliximab">Lumiliximab</a>, <a href="../../../m/a/s/Maslimomab.html" title="Maslimomab">Maslimomab</a>, <a href="../../../m/e/p/Mepolizumab.html" title="Mepolizumab">Mepolizumab</a>, <a href="../../../m/e/t/Metelimumab.html" title="Metelimumab">Metelimumab</a>, <a href="../../../m/e/t/Methotrexate.html" title="Methotrexate">Methotrexate</a>, Morolimumab, <a href="../../../m/u/r/Muromonab-CD3_9775.html" title="Muromonab-CD3">Muromonab-CD3</a>, <a href="../../../m/y/c/Mycophenolic_acid.html" title="Mycophenolic acid">Mycophenolic acid</a>, <a href="../../../n/a/t/Natalizumab.html" title="Natalizumab">Natalizumab</a>, <a href="../../../n/e/r/Nerelimomab.html" title="Nerelimomab">Nerelimomab</a>, <a href="../../../o/c/r/Ocrelizumab.html" title="Ocrelizumab">Ocrelizumab</a>, <a href="../../../o/d/u/Odulimomab.html" title="Odulimomab">Odulimomab</a>, <a href="../../../o/m/a/Omalizumab.html" title="Omalizumab">Omalizumab</a>, <a href="../../../p/a/s/Pascolizumab.html" title="Pascolizumab">Pascolizumab</a>, <a href="../../../p/e/x/Pexelizumab.html" title="Pexelizumab">Pexelizumab</a>, <a href="../../../p/i/m/Pimecrolimus.html" title="Pimecrolimus">Pimecrolimus</a>, <a href="../../../r/e/s/Reslizumab.html" title="Reslizumab">Reslizumab</a>, <a href="../../../r/o/v/Rovelizumab.html" title="Rovelizumab">Rovelizumab</a>, <a href="../../../r/u/p/Ruplizumab.html" title="Ruplizumab">Ruplizumab</a>, Safosirolimus, <a href="../../../s/i/p/Siplizumab.html" title="Siplizumab">Siplizumab</a>, <a href="../../../s/i/r/Sirolimus.html" title="Sirolimus">Sirolimus</a>, <a href="../../../t/a/c/Tacrolimus.html" title="Tacrolimus">Tacrolimus</a>, <a href="../../../t/a/l/Talizumab.html" title="Talizumab">Talizumab</a>, <a href="../../../t/e/l/Telimomab_aritox.html" title="Telimomab aritox">Telimomab aritox</a>, <a href="../../../t/e/n/Teneliximab.html" title="Teneliximab">Teneliximab</a>, <a href="../../../t/h/a/Thalidomide.html" title="Thalidomide">Thalidomide</a>, <a href="../../../t/i/c/Ticilimumab.html" title="Ticilimumab">Ticilimumab</a>, <a href="../../../t/i/l/Tilolizumab.html" title="Tilolizumab">Tilolizumab</a>, <a href="../../../t/o/c/Tocilizumab.html" title="Tocilizumab">Tocilizumab</a>, <a href="../../../t/o/r/Toralizumab.html" title="Toralizumab">Toralizumab</a>, Torolimus, <a href="../../../v/a/p/Vapaliximab.html" title="Vapaliximab">Vapaliximab</a>, <a href="../../../v/e/p/Vepalimomab.html" title="Vepalimomab">Vepalimomab</a>, <a href="../../../v/i/s/Visilizumab.html" title="Visilizumab">Visilizumab</a>, <a href="../../../z/a/n/Zanolimumab.html" title="Zanolimumab">Zanolimumab</a>, <a href="../../../z/i/r/Ziralimumab.html" title="Ziralimumab">Ziralimumab</a>, <a href="../../../z/o/l/Zolimomab_aritox.html" title="Zolimomab aritox">Zolimomab aritox</a></p>
</div>
</div>

<!-- 
Pre-expand include size: 30889 bytes
Post-expand include size: 15652 bytes
Template argument size: 5002 bytes
Maximum: 2048000 bytes
-->
<div class="printfooter">
Retrieved from "<a href="http://en.wikipedia.org../../../a/n/a/Anakinra.html">http://en.wikipedia.org../../../a/n/a/Anakinra.html</a>"</div>
	    <div id="catlinks"><p class='catlinks'><a href="../../../c/a/t/Special%7ECategories_101d.html" title="Special:Categories">Category</a>: <span dir='ltr'><a href="../../../i/m/m/Category%7EImmunosuppressive_agents_dd3c.html" title="Category:Immunosuppressive agents">Immunosuppressive agents</a></span></p></div>	    <!-- end content -->
	    <div class="visualClear"></div>
	  </div>
	</div>
      </div>
      <div id="column-one">
	<div id="p-cactions" class="portlet">
	  <h5>Views</h5>
	  <ul>
	    <li id="ca-nstab-main"
	       class="selected"	       ><a href="../../../a/n/a/Anakinra.html">Article</a></li><li id="ca-talk"
	       class="new"	       ><a href="../../../a/n/a/Talk%7EAnakinra_4635.html">Discussion</a></li><li id="ca-current"
	       	       ><a href="http://en.wikipedia.org/wiki/Anakinra">Current revision</a></li>	  </ul>
	</div>
	<div class="portlet" id="p-logo">
	  <a style="background-image: url(../../../images/wiki-en.png);"
	    href="../../../index.html"
	    title="Main Page"></a>
	</div>
	<script type="text/javascript"> if (window.isMSIE55) fixalpha(); </script>
		<div class='portlet' id='p-navigation'>
	  <h5>Navigation</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-Main-page"><a href="../../../index.html">Main page</a></li>
	     	      <li id="n-Contents"><a href="../../../c/o/n/Wikipedia%7EContents_3181.html">Contents</a></li>
	     	      <li id="n-Featured-content"><a href="../../../f/e/a/Wikipedia%7EFeatured_content_24ba.html">Featured content</a></li>
	     	      <li id="n-currentevents"><a href="../../../c/u/r/Portal%7ECurrent_events_bb60.html">Current events</a></li>
	     	    </ul>
	  </div>
	</div>
		<div class='portlet' id='p-interaction'>
	  <h5>interaction</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-About-Wikipedia"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html">About Wikipedia</a></li>
	     	      <li id="n-portal"><a href="../../../c/o/m/Wikipedia%7ECommunity_Portal_6a3c.html">Community portal</a></li>
	     	      <li id="n-contact"><a href="../../../c/o/n/Wikipedia%7EContact_us_afd6.html">Contact us</a></li>
	     	      <li id="n-sitesupport"><a href="http://wikimediafoundation.org/wiki/Fundraising">Make a donation</a></li>
	     	      <li id="n-help"><a href="../../../c/o/n/Help%7EContents_22de.html">Help</a></li>
	     	    </ul>
	  </div>
	</div>
		<div id="p-search" class="portlet">
	  <h5><label for="searchInput">Search</label></h5>
	  <div id="searchBody" class="pBody">
	    <form action="javascript:goToStatic(3)" id="searchform"><div>
	      <input id="searchInput" name="search" type="text"
	        accesskey="f" value="" />
	      <input type='submit' name="go" class="searchButton" id="searchGoButton"
	        value="Go" />
	    </div></form>
	  </div>
	</div>
	<div id="p-lang" class="portlet">
	  <h5>In other languages</h5>
	  <div class="pBody">
	    <ul>
	      	      <li>
	      <a href="../../../../fr/a/n/a/Anakinra.html">Français</a>
	      </li>
	      	      <li>
	      <a href="../../../../pl/a/n/a/Anakinra.html">Polski</a>
	      </li>
	      	    </ul>
	  </div>
	</div>
	      </div><!-- end of the left (by default at least) column -->
      <div class="visualClear"></div>
      <div id="footer">
    <div id="f-poweredbyico"><a href="http://www.mediawiki.org/"><img src="../../../skins/common/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" /></a></div>	<div id="f-copyrightico"><a href="http://wikimediafoundation.org/"><img src="../../../images/wikimedia-button.png" border="0" alt="Wikimedia Foundation"/></a></div>	<ul id="f-list">
	  	  	  <li id="f-credits">This page was last modified 17:11, 20 February 2007 by Wikipedia user <a href="../../../a/x/l/User%7EAxl_2118.html" title="User:Axl">Axl</a>. Based on work by Wikipedia user(s) <a href="../../../s/e/l/User%7ESelket_adc6.html" title="User:Selket">Selket</a>, <a href="../../../t/i/k/User%7ETikiwont_2b2d.html" title="User:Tikiwont">Tikiwont</a>, <a href="../../../c/m/d/User%7ECmdrObot_0605.html" title="User:CmdrObot">CmdrObot</a>, <a href="../../../d/a/r/User%7EDarklilac_3c11.html" title="User:Darklilac">Darklilac</a>, <a href="../../../b/l/u/User%7EBluebot_e595.html" title="User:Bluebot">Bluebot</a>, Dhn, <a href="../../../a/r/c/User%7EArcadian_5c4b.html" title="User:Arcadian">Arcadian</a>, <a href="../../../t/r/i/User%7ETristanb_d761.html" title="User:Tristanb">Tristanb</a>, <a href="../../../e/r/a/User%7EEras-mus_f9f9.html" title="User:Eras-mus">Eras-mus</a>, <a href="../../../c/e/y/User%7ECeyockey_fb55.html" title="User:Ceyockey">Ceyockey</a> and <a href="../../../j/f/d/User%7EJfdwolff_9ea6.html" title="User:Jfdwolff">Jfdwolff</a> and Anonymous user(s) of Wikipedia.</li>	  <li id="f-copyright">All text is available under the terms of the <a class='internal' href="../../../t/e/x/Wikipedia%7EText_of_the_GNU_Free_Documentation_License_702a.html" title="Wikipedia:Text of the GNU Free Documentation License">GNU Free Documentation License</a>. (See <b><a class='internal' href="../../../c/o/p/Wikipedia%7ECopyrights_92c4.html" title="Wikipedia:Copyrights">Copyrights</a></b> for details.) <br /> Wikipedia&reg; is a registered trademark of the <a href="http://www.wikimediafoundation.org">Wikimedia Foundation, Inc</a>., a US-registered <a class='internal' href="../../../5/0/1/501%28c%29.html#501.28c.29.283.29" title="501(c)(3)">501(c)(3)</a> <a href="http://wikimediafoundation.org/wiki/Deductibility_of_donations">tax-deductible</a> <a class='internal' href="../../../n/o/n/Non-profit_organization.html" title="Non-profit organization">nonprofit</a> <a href="../../../c/h/a/Charitable_organization.html" title="Charitable organization">charity</a>.<br /></li>	  <li id="f-about"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html" title="Wikipedia:About">About Wikipedia</a></li>	  <li id="f-disclaimer"><a href="../../../g/e/n/Wikipedia%7EGeneral_disclaimer_3e44.html" title="Wikipedia:General disclaimer">Disclaimers</a></li>	  	</ul>
      </div>
    </div>
  </body>
</html>
